What is Rocket Pharmaceuticals?
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology firm focused on pioneering gene therapies for debilitating genetic disorders. The company's core mission revolves around addressing critical unmet medical needs through cutting-edge research in genetic medicine. By concentrating on conditions with limited therapeutic options, Rocket Pharmaceuticals is strategically positioned to deliver transformative treatments. Their operations encompass a full spectrum from preclinical research to clinical development, driven by a commitment to scientific innovation and a collaborative approach across its multiple locations. This dedication places them at the vanguard of the gene therapy field, aiming to redefine patient care for rare diseases.
How much funding has Rocket Pharmaceuticals raised?
Rocket Pharmaceuticals has raised a total of $68M across 3 funding rounds:
Private Equity
$16.4M
Private Equity
$25.1M
Share Placement
$26.4M
Private Equity (2015): $16.4M, investors not publicly disclosed
Private Equity (2017): $25.1M, investors not publicly disclosed
Share Placement (2021): $26.4M, investors not publicly disclosed
What's next for Rocket Pharmaceuticals?
The recent major enterprise-level funding and strategic investment signal a pivotal phase for Rocket Pharmaceuticals. This influx of capital is expected to accelerate the development and clinical trials of their innovative gene therapy programs. The company is likely to expand its research and development capabilities, potentially forging new strategic partnerships to enhance its pipeline and market reach. With a clear focus on rare and serious genetic diseases, Rocket Pharmaceuticals is poised to advance its mission of bringing life-changing therapies to patients who need them most, further solidifying its position as a key player in the biopharmaceutical landscape.
See full Rocket Pharmaceuticals company page
